GCP
KRON

GSA Capital Partners’s Kronos Bio KRON Stock Holding History

GSA Capital Partners’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-57,347
Closed -$75K – 1854
2024
Q1 		$75K Buy
57,347
+32,201
+128% +$36.7K 0.01% 1511
2023
Q4 		$31K Sell
25,146
-29,375
-54% -$32.5K ﹤0.01% 1430
2023
Q3 		$71K Sell
54,521
-231,644
-81% -$374K 0.01% 1402
2023
Q2 		$492K Sell
286,165
-120,197
-30% -$191K 0.05% 750
2023
Q1 		$593K Sell
406,362
-33,564
-8% -$64.3K 0.06% 604
2022
Q4 		$713K Buy
439,926
+286,235
+186% +$659K 0.09% 389
2022
Q3 		$515K Buy
153,691
+66,845
+77% +$302K 0.07% 547
2022
Q2 		$316K Buy
86,846
+43,284
+99% +$196K 0.05% 790
2022
Q1 		$315K Buy
+43,562
New +$371K 0.04% 859

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.83B AUM 20.31% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

GSA Capital Partners's KRON Position: Q2 2024 in Review

GSA Capital Partners sold out of Kronos Bio (KRON) in Q2 2024, closing a stake of 57,347 shares — an estimated $75K sold.

GSA Capital Partners first reported a position in KRON in Q1 2022 and held it in 9 quarters. The position peaked at $713K in Q4 2022. 56 funds tracked by Wall St. Rank hold KRON as of Q2 2024.

  • GSA Capital Partners reported no remaining Kronos Bio position as of Q2 2024 after selling out during the quarter.
  • GSA Capital Partners sold 57,347 Kronos Bio shares in Q2 2024, an estimated $75K.
  • GSA Capital Partners first reported a position in Kronos Bio in Q1 2022 and held it in 9 quarters.
  • GSA Capital Partners's Kronos Bio position peaked at $713K in Q4 2022.
  • 56 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.